Detalhe da pesquisa
1.
No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.
New Microbiol
; 46(2): 154-160, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37247236
2.
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic.
New Microbiol
; 43(4): 161-165, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33135083
3.
Immune recovery and T cell subset analysis during effective treatment with maraviroc.
J Antimicrob Chemother
; 67(10): 2474-8, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22678730
4.
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach.
JAC Antimicrob Resist
; 6(3): dlae074, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38756960
5.
Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.
PLoS One
; 12(9): e0184128, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28863182
6.
Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman.
Int J Infect Dis
; 29: 100-2, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25449243
7.
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
J Acquir Immune Defic Syndr
; 56(4): e113-5, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21350358